Skip to main content
Swing Capital

Bliss GVS Pharma Ltd

NSE: BLISSGVS BSE: 506197Pharma

Incorporated in 1984, Bliss GVS Pharma Limited is engaged in manufacturing, marketing, trading and export of pharmaceutical formulations in the form of suppositories, pessaries, capsules, tablets, and syrups.

₹284
52W: ₹117 — ₹293
PE 30.5 · Book ₹109 · +161% vs book
Market Cap₹3,000 Cr
Stock P/E30.5Price to Earnings
ROCE12.8%Return on Capital
ROE8.88%Return on Equity
Div. Yield0.18%Face Value ₹1

Strengths

  • +Company has reduced debt.
  • +Company is almost debt free.

Weaknesses

  • −Stock is trading at 2.60 times its book value
  • −The company has delivered a poor sales growth of 9.41% over past five years.
  • −Company has a low return on equity of 7.87% over last 3 years.
  • −Dividend payout has been low at 11.4% of profits over last 3 years
  • −Company has high debtors of 229 days.

Shareholding Pattern

Promoters35.36%
FIIs10.45%
DIIs5.04%
Public49.15%
CategoryJun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Promoters34.9%34.82%▼0.135.1%▲0.335.29%▲0.235.44%▲0.135.39%▼0.035.36%▼0.035.36%
FIIs13.24%12.13%▼1.113.51%▲1.413.18%▼0.312.65%▼0.513.27%▲0.614.54%▲1.310.45%▼4.1
DIIs6.58%6.56%▼0.06.55%▼0.06.55%6.54%▼0.05.98%▼0.65.78%▼0.25.04%▼0.7
Public45.27%46.49%▲1.244.84%▼1.644.98%▲0.145.37%▲0.445.36%▼0.044.32%▼1.049.15%▲4.8

Financial Statements

MetricDec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Sales161164149183180156163190165212
Expenses133139122157154142131160138167
Operating Profit29252725261433302744
OPM %18%15%18%14%14%9%20%16%16%21%
Net Profit21-111917211121251932
EPS ₹1.98-1.091.851.6221.0922.351.763.06

AI Insights

Revenue Trend

Mar 2026 revenue at ₹730Cr, up 9.4% YoY. OPM at 18%.

Debt Position

Borrowings at ₹13Cr. Debt-to-equity ratio: 0.01x. Healthy balance sheet.

Capex Cycle

CWIP at ₹4Cr (1% of fixed assets). Moderate ongoing capital expenditure.

Institutional Flow

DIIs: 5.04% (-1.58pp change). FIIs: 10.45% (-6.05pp change). Promoters hold 35.36%.

Margin & Efficiency

ROCE declining from 24% (Mar 2015) to 13% (Mar 2026). Working capital days: 274.

Valuation

PE 30.5x with 12.8% ROCE. Price is 161% above book value of ₹109. Dividend yield: 0.18%.

Recent Announcements